PL1962886T6 - Stabilne formulacje białkowe - Google Patents

Stabilne formulacje białkowe

Info

Publication number
PL1962886T6
PL1962886T6 PL06846683.8T PL06846683T PL1962886T6 PL 1962886 T6 PL1962886 T6 PL 1962886T6 PL 06846683 T PL06846683 T PL 06846683T PL 1962886 T6 PL1962886 T6 PL 1962886T6
Authority
PL
Poland
Prior art keywords
protein formulations
stable protein
stable
formulations
protein
Prior art date
Application number
PL06846683.8T
Other languages
English (en)
Other versions
PL1962886T3 (pl
Inventor
Manisha M. Dali
Charles E. Dahlheim
Sunita Borsadia
Vijay H. Naringrekar
Rajesh B. Gandhi
Manoj Nerurkar
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38057529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1962886(T6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of PL1962886T3 publication Critical patent/PL1962886T3/pl
Publication of PL1962886T6 publication Critical patent/PL1962886T6/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
PL06846683.8T 2005-12-20 2006-12-19 Stabilne formulacje białkowe PL1962886T6 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75215005P 2005-12-20 2005-12-20
PCT/US2006/062297 WO2007076354A2 (en) 2005-12-20 2006-12-19 Stable protein formulations
EP06846683.8A EP1962886B2 (en) 2005-12-20 2006-12-19 Stable protein formulations

Publications (2)

Publication Number Publication Date
PL1962886T3 PL1962886T3 (pl) 2014-03-31
PL1962886T6 true PL1962886T6 (pl) 2023-03-13

Family

ID=38057529

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06846683.8T PL1962886T6 (pl) 2005-12-20 2006-12-19 Stabilne formulacje białkowe

Country Status (24)

Country Link
US (1) US8476239B2 (pl)
EP (1) EP1962886B2 (pl)
JP (2) JP5247467B2 (pl)
KR (1) KR101378194B1 (pl)
CN (3) CN101584858A (pl)
AR (2) AR058567A1 (pl)
AU (1) AU2006330593B2 (pl)
BR (1) BRPI0622256A2 (pl)
CA (1) CA2634547C (pl)
CL (1) CL2010000816A1 (pl)
DK (1) DK1962886T4 (pl)
EA (1) EA014232B1 (pl)
ES (1) ES2436616T5 (pl)
HR (1) HRP20131196T4 (pl)
IL (1) IL192104A (pl)
NO (1) NO347247B1 (pl)
NZ (1) NZ569108A (pl)
PE (1) PE20071063A1 (pl)
PL (1) PL1962886T6 (pl)
PT (1) PT1962886E (pl)
RS (1) RS53127B2 (pl)
SG (1) SG153832A1 (pl)
TW (3) TWI393575B (pl)
WO (1) WO2007076354A2 (pl)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101378194B1 (ko) * 2005-12-20 2014-03-27 브리스톨-마이어스 스큅 컴퍼니 안정한 단백질 제제
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
JP5096369B2 (ja) 2005-12-20 2012-12-12 ブリストル−マイヤーズ スクイブ カンパニー 組成物および組成物の製造方法
US7915222B2 (en) 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
ES2624484T3 (es) 2008-10-06 2017-07-14 3-D Matrix, Ltd. Tapón de tejido
US9216388B2 (en) * 2009-06-23 2015-12-22 Ge Healthcare Bio-Sciences Ab Simulator device
GB201009676D0 (en) * 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
JP5847418B2 (ja) 2011-03-30 2016-01-20 富士フイルム株式会社 細胞接着性タンパク質
US20140147418A1 (en) * 2011-04-15 2014-05-29 The Us Of America, As Represented By The Secretary Department Of Health And Human Services Aav mediated ctla-4 gene transfer to treat sjogren's syndrome
WO2012145523A2 (en) 2011-04-20 2012-10-26 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Aav mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物
SG2014010417A (en) 2011-10-07 2014-06-27 Takeda Pharmaceutical 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
SMT202000091T1 (it) 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
HK1200718A1 (en) 2011-10-18 2015-08-14 科荣生生物科学公司 Etanercept formulations stabilized with sodium chloride
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
SI2867251T1 (sl) 2012-06-29 2019-12-31 Bristol-Myers Squibb Company Postopki za zmanjšanje agregacije glikoproteina
EP3466964A1 (en) 2012-07-06 2019-04-10 3-D Matrix Ltd. Fill-finish process for peptide solutions
WO2014011672A1 (en) * 2012-07-09 2014-01-16 Coherus Biosciences, Inc. Etanercept formulations exhibiting marked reduction in sub-visible particles
DK2890791T3 (da) 2012-08-31 2019-06-11 Us Health Aav-medieret aquaporingenoverførsel til behandling af sjögrens syndrom
SG11201501715QA (en) 2012-09-07 2015-05-28 Coherus Biosciences Inc Stable aqueous formulations of adalimumab
PE20150996A1 (es) 2012-09-11 2015-08-01 Coherus Biosciences Inc Etanercept correctamente plegado de alta pureza y excelente rendimiento
US10450361B2 (en) 2013-03-15 2019-10-22 Momenta Pharmaceuticals, Inc. Methods related to CTLA4-Fc fusion proteins
ES2708759T3 (es) 2013-05-13 2019-04-11 Momenta Pharmaceuticals Inc Procedimientos para el tratamiento de la neurodegeneración
CN103385852B (zh) * 2013-08-06 2015-03-11 南京正大天晴制药有限公司 一种盐酸法舒地尔注射液及其制备方法
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
EP3058084A4 (en) 2013-10-16 2017-07-05 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
WO2015138514A1 (en) 2014-03-10 2015-09-17 3-D Matrix, Ltd. Self-assembling peptide compositions
JP6684719B2 (ja) 2014-03-10 2020-04-22 株式会社スリー・ディー・マトリックス ペプチド組成物の滅菌および濾過
BR112016018813A2 (pt) 2014-03-19 2017-10-10 Bristol Myers Squibb Co métodos para tratar rejeição de transplante usando um anticorpo de domínio direcionado contra cd40l
CN106456784A (zh) * 2014-04-16 2017-02-22 拜康有限公司 包含摩尔过量的山梨醇的稳定蛋白质制剂
AU2015249656A1 (en) 2014-04-25 2016-11-03 Bristol-Myers Squibb Company Use of CTLA4 compound for achieving drug-free remission in subjects with early RA
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
WO2015198199A1 (en) 2014-06-23 2015-12-30 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof.
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US20170107248A1 (en) 2014-06-23 2017-04-20 Novartis Ag Site specific protein modifications
CA2962768C (en) 2014-10-01 2023-10-10 Alyssa M. Larson Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
WO2016080367A1 (ja) 2014-11-18 2016-05-26 塩野義製薬株式会社 安定化されたペプチド組成物
CA2972871A1 (en) 2015-01-23 2016-07-28 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
US10144779B2 (en) 2015-05-29 2018-12-04 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
DK3347031T3 (da) * 2015-09-11 2021-04-26 Nutrition & Biosciences Usa 1 Llc Sammensætning, der omfatter et protein og en polyalkoxyfedtforbindelse
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
BR112018010211A2 (pt) * 2015-12-07 2019-02-05 Merck Patent Gmbh formulação farmacêutica aquosa compreendendo anticorpo anti-pd-l1 avelumab
WO2017109706A1 (en) 2015-12-22 2017-06-29 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
WO2017120092A1 (en) 2016-01-06 2017-07-13 3-D Matrix, Ltd. Combination compositions
EP3192805A1 (en) 2016-01-15 2017-07-19 Humanitas Mirasole S.p.A. Inhibitors of t cell activation or stimulation and uses thereof
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
MA50949B1 (fr) 2016-12-07 2023-12-29 Memorial Sloan Kettering Cancer Center Anticorps anti-ctla-4 et leurs procédés d'utilisation
AU2018271915B2 (en) 2017-05-24 2025-03-27 Als Therapy Development Institute Therapeutic anti-CD40 ligand antibodies
SMT202400277T1 (it) 2017-12-22 2024-09-16 Novartis Ag Trattamento di disturbi metabolici con varianti di fgf21
CN108014338A (zh) * 2018-01-22 2018-05-11 安徽未名生物医药有限公司 一种注射用巴利昔单抗冻干粉针及其制备方法
AU2019274826A1 (en) 2018-05-25 2021-01-07 Dr. Reddy's Laboratories Ltd. Stable fusion protein formulation
WO2019224843A1 (en) * 2018-05-25 2019-11-28 Dr. Reddy's Laboratories Ltd. Ctla4-ig fusion protein formulation
WO2020003139A2 (en) * 2018-06-26 2020-01-02 Lupin Limited Stable lyophilized dosage form of protein
CN113476484A (zh) * 2018-06-29 2021-10-08 武汉纽福斯生物科技有限公司 治疗遗传性视神经病变的组合物和方法
JP2022513626A (ja) 2018-11-26 2022-02-09 ノバルティス アーゲー Ｌｐｌ－ｇｐｉｈｂｐ１融合ポリペプチド
AU2020208909B2 (en) 2019-01-15 2025-02-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Mutated interleukin-34 (IL-34) polypeptides and uses thereof in therapy
EP3914282A1 (en) 2019-01-25 2021-12-01 Ospedale San Raffaele S.r.l. Inhibitor of dux4 and uses thereof
GB201913697D0 (en) 2019-09-23 2019-11-06 King S College London DAP10/DAP12 fusion polypeptides
CA3161118A1 (en) * 2019-12-20 2021-06-24 Anthos Therapeutics, Inc. Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies
GB202003277D0 (en) 2020-03-06 2020-04-22 King S College London Therapeutic agents
GB202007655D0 (en) 2020-05-22 2020-07-08 King S College London Chimeric nkg2d protein
WO2022162704A1 (en) * 2021-02-01 2022-08-04 Dr. Reddy's Laboratories Limited Compositions comprising fusion protein and analytical attributes thereof
DK4171622T3 (da) 2021-03-23 2024-08-05 King S College London Sammensætninger omfattende nkg2d- cxcr2- og dap10/dap12- fusionspolypeptider og fremgangsmdåer til anvendelse deraf
CN113925963B (zh) * 2021-10-15 2023-08-11 江苏太平洋美诺克生物药业股份有限公司 一种稳定的包含抗cd147单克隆抗体的药物制剂
GB202214120D0 (en) 2022-09-27 2022-11-09 King S College London Compositions comprising NKG2D, CXCR2, and DAP10/DAP12 fusion polypeptides and methods of use thereof
EP4593876A2 (en) * 2022-09-29 2025-08-06 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer
EP4389762A1 (en) 2022-12-23 2024-06-26 Ospedale San Raffaele S.r.l. Inhibitors of dux4 activity and their use in therapy.
WO2025196207A1 (en) 2024-03-20 2025-09-25 King's College London Compositions and methods for use in depleting senescent cells and treating aging

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994019020A1 (en) * 1993-02-23 1994-09-01 Genentech, Inc. Excipient stabilization of polypeptides treated with organic solvents
DE4405426A1 (de) * 1994-02-21 1995-08-24 Boehringer Mannheim Gmbh Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
DK1516628T3 (da) * 1995-07-27 2013-09-08 Genentech Inc Stabil, isotonisk lyofiliseret proteinformulering
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
WO2003005465A1 (en) 2001-04-25 2003-01-16 Quallion, Llc Rechargeable lithium battery for tolerating discharge to zero volts
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US7183376B2 (en) * 2000-06-23 2007-02-27 Maxygen, Inc. Variant B7 co-stimulatory molecules
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
PL212205B1 (pl) * 2000-07-03 2012-08-31 Bristol Myers Squibb Co Zastosowanie rozpuszczalnej zmutowanej cząsteczki CTLA4
AU2002243905B2 (en) * 2001-01-26 2007-11-08 Emory University Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
JP2005521640A (ja) 2001-11-13 2005-07-21 ジェネンテック・インコーポレーテッド Ａｐｏ−２リガンド／ＴＲＡＩＬ製剤
DE10163459A1 (de) * 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
DE10204792A1 (de) 2002-02-06 2003-08-14 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Immuncytokine
DE60334678D1 (de) * 2002-02-14 2010-12-09 Chugai Pharmaceutical Co Ltd Antikörper enthaltende pharmazeutische lösungen
SI1576182T2 (sl) 2002-12-23 2020-07-31 Bristol-Myers Squibb Company Izboljšava kvalitete izdelka v procesih pridelave beljakovin v celični kulturi sesalcev
TWI312368B (en) * 2002-12-23 2009-07-21 Bristol Myers Squibb Compan Mammalian cell culture processes for protein production
HRP20050934B1 (hr) * 2003-04-04 2014-09-26 Genentech, Inc. Formulacije s visokom koncentracijom antitijela i proteina
CA2762015A1 (en) * 2003-08-04 2005-02-24 Bristol-Myers Squibb Company Methods for treating cardiovascular disease using a soluble ctla4 molecule
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US7790679B2 (en) * 2005-08-05 2010-09-07 Amgen Inc. Pharmaceutical formulations
KR101378194B1 (ko) * 2005-12-20 2014-03-27 브리스톨-마이어스 스큅 컴퍼니 안정한 단백질 제제

Also Published As

Publication number Publication date
JP5538309B2 (ja) 2014-07-02
CA2634547C (en) 2016-10-11
SG153832A1 (en) 2009-07-29
HRP20131196T1 (hr) 2014-01-31
TW201008595A (en) 2010-03-01
JP2009524595A (ja) 2009-07-02
EP1962886B2 (en) 2022-02-23
BRPI0620186A2 (pt) 2010-07-06
ES2436616T5 (es) 2022-05-27
US8476239B2 (en) 2013-07-02
EP1962886B1 (en) 2013-10-16
HRP20131196T4 (hr) 2022-06-10
WO2007076354A2 (en) 2007-07-05
CN101822820A (zh) 2010-09-08
NO20082628L (no) 2008-07-15
NO347247B1 (no) 2023-07-31
KR20080078070A (ko) 2008-08-26
DK1962886T4 (da) 2022-05-02
ES2436616T3 (es) 2014-01-03
JP2011246470A (ja) 2011-12-08
AU2006330593B2 (en) 2012-07-26
RS53127B (sr) 2014-06-30
RS53127B2 (sr) 2022-06-30
AR058567A1 (es) 2008-02-13
IL192104A (en) 2015-01-29
AR097561A2 (es) 2016-03-23
KR101378194B1 (ko) 2014-03-27
AU2006330593A1 (en) 2007-07-05
EA014232B1 (ru) 2010-10-29
JP5247467B2 (ja) 2013-07-24
CN101378773A (zh) 2009-03-04
IL192104A0 (en) 2008-12-29
HK1114568A1 (en) 2008-11-07
CA2634547A1 (en) 2007-07-05
PL1962886T3 (pl) 2014-03-31
TW200738261A (en) 2007-10-16
BRPI0622256A2 (pt) 2011-08-09
DK1962886T3 (da) 2014-01-13
EP1962886A2 (en) 2008-09-03
CL2010000816A1 (es) 2011-02-11
TW201008596A (en) 2010-03-01
WO2007076354A3 (en) 2007-08-16
EA200801570A1 (ru) 2008-12-30
US20100166774A1 (en) 2010-07-01
CN101378773B (zh) 2013-03-13
CN101584858A (zh) 2009-11-25
NZ569108A (en) 2011-09-30
PE20071063A1 (es) 2007-10-24
TWI393575B (zh) 2013-04-21
PT1962886E (pt) 2014-01-07

Similar Documents

Publication Publication Date Title
IL192104A0 (en) Stable protein formulations
GB2424581B (en) Formulations
EP1988922A4 (en) PROTEIN FORMULATIONS
IL188102A0 (en) Self-buffering protein formulations
IL185773A0 (en) Formulations
EP1909584A4 (en) PRENYLFLAVONOID FORMULATIONS
IL192149A0 (en) Stable s-nitrosothiol formulations
EP1951693A4 (en) SOLID FORMULATIONS
GB0514482D0 (en) Protein
SI1962886T2 (sl) Stabilne proteinske formulacije
IL179208A0 (en) Intereferon formulations
GB0513653D0 (en) Protein stability
GB0526322D0 (en) Formulations
GB0520388D0 (en) Formulations
GB0518878D0 (en) Formulations
GB0522917D0 (en) Formulations
GB0504106D0 (en) Novel formulations
GB0500917D0 (en) Novel formulations
GB0500915D0 (en) Novel formulations
GB0500913D0 (en) Novel formulations
GB0519090D0 (en) Novel formulations
GB0500912D0 (en) Novel formulations
GB0522828D0 (en) Novel formulations
GB0515438D0 (en) Protein
GB0515180D0 (en) Protein